USA - NASDAQ:AGTC - US03820J1007 - Common Stock
ChartMill assigns a Buy % Consensus number of 50% to AGTC. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-10-25 | Wells Fargo | Maintains | Equal-Weight |
| 2022-10-25 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2022-10-24 | Stifel | Downgrade | Buy -> Hold |
| 2022-10-24 | Wedbush | Downgrade | Outperform -> Neutral |
| 2022-10-04 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2022-09-30 | Stifel | Maintains | Buy |
| 2022-09-30 | HC Wainwright & Co. | Maintains | Buy |
| 2022-09-29 | BTIG | Downgrade | Buy -> Neutral |
| 2022-09-28 | Chardan Capital | Maintains | Buy |
| 2022-05-18 | Chardan Capital | Maintains | Buy |
| 2021-06-15 | BTIG | Initiate | Buy |
| 2021-03-02 | Stifel | Initiate | Buy |
10 analysts have analysed AGTC and the average price target is 0.37 USD. This implies a price decrease of -6.71% is expected in the next year compared to the current price of 0.3936.
The consensus rating for APPLIED GENETIC TECHNOLOGIES (AGTC) is 50 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
The number of analysts covering APPLIED GENETIC TECHNOLOGIES (AGTC) is 10.